Treatment of Basal Cell Carcinoma of Skin in Metastatic Basal Cell Carcinoma
Metastatic basal cell carcinoma (mBCC) is a form of advanced BCC that requires a targeted systemic approach. This protocol covers the evidence-based management of mBCC as a distinct clinical entity within the advanced BCC spectrum.
Clinical Scenario
This protocol applies to patients with metastatic basal cell carcinoma. Advanced BCC encompasses both locally advanced BCC (laBCC) and metastatic BCC (mBCC), with mBCC requiring its own specific systemic management strategy.
Treatment Approach
The structured protocol for metastatic BCC incorporates anti-PD1 immunotherapy as a core component of the systemic regimen.
Full regimen details, sequencing, and criteria available in the protocol →
References
DOI: 10.1016/j.ejca.2023.113254
- Advanced BCC includes locally advanced BCC (laBCC) and metastatic BCC (mBCC).
- Anti-PD1 immunotherapy should be offered as second-line treatment in patients who progress or have contraindications to hedgehog inhibitors.
- Eighty-four laBCC patients received cemiplimab with the conventional dose of 350 mg intravenously every 3 weeks for up to 93 weeks or until progression or unacceptable toxicity.
View source ↗